Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells

Molecular Cancer Therapeutics

Volumn 5, Issue 9, 2006, Pages 2172-2181

  García Morales, Pilar ^a   Hernando, Eva ^c   Carrasco García, Estefanía ^a   Menéndez Gutierrez, María Piedad ^a   Saceda, Miguel ^a,b   Martínez Lacaci, Isabel ^a  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; CYCLIN D3; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEASOME INHIBITOR; PROTEIN P70; RAPAMYCIN; RETINOBLASTOMA PROTEIN; S6 KINASE; SMALL INTERFERING RNA; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FLUORESCENCE ACTIVATED CELL SORTING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; UBIQUITINATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLIN D3; CYCLIN-DEPENDENT KINASE 2; CYCLINS; DOWN-REGULATION; HUMANS; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASES; RECEPTOR, ERBB-2; RETINOBLASTOMA; RNA, MESSENGER; SIROLIMUS; TOR SERINE-THREONINE KINASES; UBIQUITINS;

EID: 33749566551     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0363     Document Type: Article

References (45)

1. Thomas GV. mTOR and cancer: reason for dancing at the crossroads? Curr Opin Genet Dev 2006;16:78-84.
2. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000;103:253-62.
3. Beretta L, Gingras AC, Svitkin YV, Hall MN, Sonenberg N. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J 1996;15:658-64.
4. Sonenberg N, Gingras AC. The mRNA 5′ cap-binding protein eIF4E and control of cell growth. Curr Opin Cell Biol 1998;10:268-75.
5. s6k. FEBS Lett 1997;410:78-82.
6. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001;15:807-26.
7. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985;229:974-6.
8. Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 1999;18:2149-64.
9. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998;10:262-7.
10. Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 1998; 273:29864-72.
11. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000;60:3689-95.
12. 1-phase progression. Genes Dev 1999;13:1501-12.
13. Bartek J, Lukas J. Cell cycle. Order from destruction. Science 2001; 294:66-7.
14. Kraus MH, Popescu NC, Amsbaugh SC, King CR. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 1987;6: 605-10.
15. Alimandi M, Romano A, Curia MC, et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995;10:1813-21.
16. Granville CA, Memmott RM, Gills JJ, Dennis PA. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 2006;12:679-89.
17. Janus A, Robak T, Smolewski P. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett 2005;10:479-98.
18. Johnston SR. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer. Clin Cancer Res 2006;12:1061-8s.
19. White MJ, DiCaprio MJ, Greenberg DA. Assessment of neuronal viability with Alamar Blue in cortical and granule cell cultures. J Neurosci Methods 1996;70:195-200.
20. 2/M-phase subpopulations in mammalian cell nuclei using side scatter and DNA content measurements. Cytometry 1990;11:813-21.
21. Hermanto U, Zong CS, Wang LH. ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth. Oncogene 2001;20:7551-62.
22. Aoki M, Blazek E, Vogt PK. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci U S A 2001;98:136-41.
23. 1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 1998;273: 14424-9.
24. s6K pathway in human pancreatic cancer cells. Cancer Res 1999;59: 3581-7.
25. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002;73:1565-72.
26. 1/S-phase growth arrest in T lymphocytes. J Biol Chem 1993;268: 3734-8.
27. 1 of an osteosarcoma cell line. J Biol Chem 1993;268:22825-9.
28. Yu K, Toral-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001;8:249-58.
29. Noh WC, Mondesire WH, Peng J, et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 2004;10:1013-23.
30. Feng LX, Ravindranath N, Dym M. Stem cell factor/c-kit up-regulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3-kinase/p70 S6 kinase pathway in spermatogonia. J Biol Chem 2000; 275:25572-6.
31. 1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 2003;101:278-85.
32. Hleb M, Murphy S, Wagner EF, et al. Evidence for cyclin D3 as a novel target of rapamycin in human T lymphocytes. J Biol Chem 2004;279: 31948-55.
33. Breslin EM, White PC, Shore AM, Clement M, Brennan P. LY294002 and rapamycin co-operate to inhibit T-cell proliferation. Br J Pharmacol 2005;144:791-800.
34. Pallet N, Thervet E, Le Corre D, et al. Rapamycin inhibits human renal epithelial cell proliferation: effect on cyclin D3 mRNA expression and stability. Kidney Int 2005;67:2422-33.
35. Herrmann F, Lehr HA, Drexler I, et al. HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res 2004;64:215-20.
36. Diehl JA, Zindy F, Shen, CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 1997;11:957-72.
37. Russell A, Thompson MA, Hendley J, Trute L, Armes J, Germain D. Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer. Oncogene 1999;18:1983-91.
38. Wong SC, Chan JK, Lee KC, Hsiao WL. Differential expression of p16/p21/ p27 and cyclin D1/D3, and their relationships to cell proliferation, apoptosis, and tumour progression in invasive ductal carcinoma of the breast. J Pathol 2001;194:35-42.
39. Pirkmaier A, Dow R, Ganiatsas S, et al. Alternative mammary oncogenic pathways are induced by D-type cyclins; MMTV-cyclin D3 transgenic mice develop squamous cell carcinoma. Oncogene 2003;22: 4425-33.
40. Liu M, Howes A, Lesperance J, et al. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. Cancer Res 2005;65:5325-36.
41. Ito D, Fujimoto K, Mori T, et al. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int J Cancer 2006;118:2337-43.
42. Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG, Mills GB. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 1995;55:1982-8.
43. Rao RD, Mladek AC, Lamont JD, et al. Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia 2005;7:921-9.
44. Meric-Bernstam F, Esteva FJ. Potential role of mammalian target of rapamycin inhibitors in breast cancer therapy. Clin Breast Cancer 2005;6: 357-60.
45. Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005;23:5314-22.